Comparison of teneligliptin and other gliptin-based regimens in addressing insulin resistance and glycemic control in type 2 diabetic patients: a cross-sectional study
CONCLUSION: Teneligliptin seems to be cost-effective and safer option in T2DM subjects who were not adequately controlled with metformin and sulfonylureas. However, further prospective studies are needed.PMID:38078453 | DOI:10.1080/17446651.2023.2290486
Source: Expert Review of Endocrinology and Metabolism - Category: Endocrinology Authors: Harmanjit Singh Ravi Rohilla Shivani Jaswal Mandeep Singla Source Type: research
More News: Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Fortamet | Glimepiride | Insulin | Metformin | Study